JP2020500006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500006A5 JP2020500006A5 JP2019520053A JP2019520053A JP2020500006A5 JP 2020500006 A5 JP2020500006 A5 JP 2020500006A5 JP 2019520053 A JP2019520053 A JP 2019520053A JP 2019520053 A JP2019520053 A JP 2019520053A JP 2020500006 A5 JP2020500006 A5 JP 2020500006A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- lag
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 102000017578 LAG3 Human genes 0.000 claims 6
- 101150030213 Lag3 gene Proteins 0.000 claims 6
- 238000000684 flow cytometry Methods 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 102000043131 MHC class II family Human genes 0.000 claims 3
- 108091054438 MHC class II family Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000012875 competitive assay Methods 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000013642 negative control Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 239000004175 ponceau 4R Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 101001137986 Mus musculus Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 231100000655 enterotoxin Toxicity 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000004073 interleukin-2 production Effects 0.000 claims 1
- 230000037041 intracellular level Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022195869A JP7488323B2 (ja) | 2016-10-13 | 2022-12-07 | 抗ｌａｇ－３抗体および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407678P | 2016-10-13 | 2016-10-13 | |
| US62/407,678 | 2016-10-13 | ||
| PCT/EP2017/076188 WO2018069500A2 (en) | 2016-10-13 | 2017-10-13 | Anti-lag-3 antibodies and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195869A Division JP7488323B2 (ja) | 2016-10-13 | 2022-12-07 | 抗ｌａｇ－３抗体および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500006A JP2020500006A (ja) | 2020-01-09 |
| JP2020500006A5 true JP2020500006A5 (enExample) | 2020-11-19 |
| JP7212821B2 JP7212821B2 (ja) | 2023-01-26 |
Family
ID=60201531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520053A Active JP7212821B2 (ja) | 2016-10-13 | 2017-10-13 | 抗ｌａｇ－３抗体および組成物 |
| JP2022195869A Active JP7488323B2 (ja) | 2016-10-13 | 2022-12-07 | 抗ｌａｇ－３抗体および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022195869A Active JP7488323B2 (ja) | 2016-10-13 | 2022-12-07 | 抗ｌａｇ－３抗体および組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11390676B2 (enExample) |
| EP (1) | EP3526255A2 (enExample) |
| JP (2) | JP7212821B2 (enExample) |
| KR (2) | KR102583190B1 (enExample) |
| CN (4) | CN117567622A (enExample) |
| AU (1) | AU2017342071B2 (enExample) |
| BR (1) | BR112019006876A2 (enExample) |
| CA (1) | CA3039140A1 (enExample) |
| CL (1) | CL2019000979A1 (enExample) |
| CO (1) | CO2019004003A2 (enExample) |
| EA (1) | EA201990912A1 (enExample) |
| IL (1) | IL265844B2 (enExample) |
| MA (1) | MA46525A (enExample) |
| MX (1) | MX2019004241A (enExample) |
| MY (1) | MY203971A (enExample) |
| PE (1) | PE20190911A1 (enExample) |
| PH (1) | PH12019500668B1 (enExample) |
| RU (1) | RU2755503C2 (enExample) |
| SA (1) | SA519401522B1 (enExample) |
| SG (1) | SG10201912940WA (enExample) |
| TN (1) | TN2019000099A1 (enExample) |
| TW (1) | TWI784976B (enExample) |
| UA (1) | UA127050C2 (enExample) |
| WO (1) | WO2018069500A2 (enExample) |
| ZA (1) | ZA201901924B (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019007369A2 (pt) | 2016-10-11 | 2019-07-16 | Agenus Inc | anticorpos anti-lag-3 e métodos de uso dos mesmos |
| US11390676B2 (en) * | 2016-10-13 | 2022-07-19 | Symphogen A/S | Anti-LAG-3 antibodies and compositions |
| AU2018247916B2 (en) * | 2017-04-05 | 2025-04-24 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
| US11723975B2 (en) | 2017-05-30 | 2023-08-15 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
| EP3630842A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| IL322104A (en) | 2017-05-30 | 2025-09-01 | Bristol Myers Squibb Co | Treatment of lag-3 positive tumors |
| CN115057931B (zh) * | 2018-02-28 | 2025-08-22 | 广州誉衡生物科技有限公司 | 抗人lag-3抗体及其用途 |
| US11795221B2 (en) * | 2018-02-28 | 2023-10-24 | WuXi Biologics Ireland Limited | Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof |
| CA3097916A1 (en) | 2018-05-03 | 2019-11-07 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom |
| CN110615840A (zh) * | 2018-06-19 | 2019-12-27 | 信达生物制药(苏州)有限公司 | 全人源的抗lag-3抗体及其应用 |
| US20210238287A1 (en) | 2018-07-26 | 2021-08-05 | Bristol-Myers Squibb Company | LAG-3 Combination Therapy for the Treatment of Cancer |
| SG11202102864XA (en) | 2018-10-19 | 2021-05-28 | Bristol Myers Squibb Co | Combination therapy for melanoma |
| CN111620949A (zh) * | 2019-02-28 | 2020-09-04 | 三生国健药业（上海）股份有限公司 | 结合人lag-3的抗体、其制备方法和用途 |
| EP3969040A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| IT201900011676A1 (it) * | 2019-07-12 | 2021-01-12 | St Superiore Di Sanita | Anticorpo ricombinante umano contro il recettore di membrana LAG3, suoi usi medici e diagnostici. |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| BR112022003956A2 (pt) * | 2019-09-06 | 2022-05-24 | Symphogen As | Anticorpos anti-cd73 |
| AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| EP4054723A1 (en) | 2019-11-08 | 2022-09-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| EP4100426A1 (en) | 2020-02-06 | 2022-12-14 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
| EP4126048A4 (en) * | 2020-04-03 | 2025-01-15 | Yuhan Corporation | Engineered antibodies that bind lag3 |
| CN111808192B (zh) * | 2020-06-05 | 2022-02-15 | 北京天广实生物技术股份有限公司 | 结合lag3的抗体及其用途 |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| EP4204095A1 (en) | 2020-08-28 | 2023-07-05 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| EP4284950A4 (en) | 2021-01-29 | 2024-12-25 | Board of Regents, The University of Texas System | METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| US20240279225A1 (en) | 2021-04-08 | 2024-08-22 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| EP4373851A2 (en) | 2021-07-19 | 2024-05-29 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| JP2024534787A (ja) | 2021-08-16 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規なｉｌ２７受容体アゴニスト及びその使用方法 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| CN118765285A (zh) | 2022-01-26 | 2024-10-11 | 百时美施贵宝公司 | 用于肝细胞癌的组合疗法 |
| CA3251366A1 (en) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | POLYTHERAPY AGAINST COLORECTAL CARCINOMA |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| AU2023230110A1 (en) | 2022-03-08 | 2024-10-24 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| US20250340668A1 (en) | 2022-05-11 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Multispecific binding molecule proproteins and uses thereof |
| JP2025519158A (ja) | 2022-05-27 | 2025-06-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インターロイキン－２プロタンパク質及びその使用 |
| JP2025518785A (ja) | 2022-06-02 | 2025-06-19 | ブリストル－マイヤーズ スクイブ カンパニー | 抗体組成物及びその使用方法 |
| US20230391844A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| JP2025529805A (ja) | 2022-08-18 | 2025-09-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インターフェロンプロタンパク質及びその使用 |
| KR20250113508A (ko) | 2022-12-01 | 2025-07-25 | 메디뮨 리미티드 | 항-pd-l1 및 항-cd73 항체를 포함하는 암 치료를 위한 병용 요법 |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| CN120731228A (zh) | 2022-12-21 | 2025-09-30 | 百时美施贵宝公司 | 肺癌的组合疗法 |
| EP4649088A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| US20240287186A1 (en) | 2023-02-28 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | T cell activators and methods of use thereof |
| WO2024192033A1 (en) | 2023-03-13 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025056011A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| CN119971023A (zh) * | 2023-11-02 | 2025-05-13 | 正大天晴(广州)医药有限公司 | 含抗lag-3抗体的药物组合物及其用途 |
| WO2025106469A1 (en) | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
| US20250179137A1 (en) | 2023-12-05 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| WO2025184211A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
| WO2025255480A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| USRE38313E1 (en) | 1994-05-06 | 2003-11-11 | Institut Gustave Roussy | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX2012012441A (es) * | 2010-05-04 | 2013-02-26 | Merrimack Pharmaceuticals Inc | Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos. |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| SI2970464T1 (sl) * | 2013-03-15 | 2020-08-31 | Glaxosmithkline Intellectual Propety Development Limited | Anti-LAG-3 vezavni proteini |
| KR20160055269A (ko) | 2013-09-20 | 2016-05-17 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CA2936962C (en) * | 2014-03-14 | 2024-03-05 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| MA41463A (fr) * | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| KR20220103806A (ko) | 2016-05-18 | 2022-07-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료용 항-pd1 및 항-lag3 항체 |
| US11390676B2 (en) * | 2016-10-13 | 2022-07-19 | Symphogen A/S | Anti-LAG-3 antibodies and compositions |
| AU2018247916B2 (en) | 2017-04-05 | 2025-04-24 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
-
2017
- 2017-10-13 US US16/340,855 patent/US11390676B2/en active Active
- 2017-10-13 PE PE2019000815A patent/PE20190911A1/es unknown
- 2017-10-13 CN CN202311394766.8A patent/CN117567622A/zh active Pending
- 2017-10-13 IL IL265844A patent/IL265844B2/en unknown
- 2017-10-13 UA UAA201904924A patent/UA127050C2/uk unknown
- 2017-10-13 BR BR112019006876A patent/BR112019006876A2/pt unknown
- 2017-10-13 JP JP2019520053A patent/JP7212821B2/ja active Active
- 2017-10-13 CN CN201780074499.2A patent/CN110062766B/zh active Active
- 2017-10-13 EA EA201990912A patent/EA201990912A1/ru unknown
- 2017-10-13 MA MA046525A patent/MA46525A/fr unknown
- 2017-10-13 KR KR1020197012672A patent/KR102583190B1/ko active Active
- 2017-10-13 TN TNP/2019/000099A patent/TN2019000099A1/en unknown
- 2017-10-13 AU AU2017342071A patent/AU2017342071B2/en active Active
- 2017-10-13 MX MX2019004241A patent/MX2019004241A/es unknown
- 2017-10-13 CN CN202311388116.2A patent/CN117567621A/zh active Pending
- 2017-10-13 PH PH1/2019/500668A patent/PH12019500668B1/en unknown
- 2017-10-13 MY MYPI2019001727A patent/MY203971A/en unknown
- 2017-10-13 SG SG10201912940WA patent/SG10201912940WA/en unknown
- 2017-10-13 TW TW106135145A patent/TWI784976B/zh active
- 2017-10-13 EP EP17791987.5A patent/EP3526255A2/en active Pending
- 2017-10-13 KR KR1020237032304A patent/KR102846713B1/ko active Active
- 2017-10-13 CN CN202311395764.0A patent/CN117567623A/zh active Pending
- 2017-10-13 CA CA3039140A patent/CA3039140A1/en active Pending
- 2017-10-13 WO PCT/EP2017/076188 patent/WO2018069500A2/en not_active Ceased
- 2017-10-13 RU RU2019113790A patent/RU2755503C2/ru active
-
2019
- 2019-03-28 ZA ZA2019/01924A patent/ZA201901924B/en unknown
- 2019-04-10 SA SA519401522A patent/SA519401522B1/ar unknown
- 2019-04-11 CL CL2019000979A patent/CL2019000979A1/es unknown
- 2019-04-23 CO CONC2019/0004003A patent/CO2019004003A2/es unknown
-
2022
- 2022-06-07 US US17/834,497 patent/US11834503B2/en active Active
- 2022-12-07 JP JP2022195869A patent/JP7488323B2/ja active Active
-
2023
- 2023-10-19 US US18/490,500 patent/US20240052032A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500006A5 (enExample) | ||
| RU2019113790A (ru) | Анти-lag-3 антитела и их композиции | |
| JP2023027199A5 (enExample) | ||
| ES2777603T3 (es) | Anticuerpos PD-L1 ("ligando de muerte programada 1") | |
| TWI564022B (zh) | 利用ｉｌ-１７拮抗劑治療牛皮癬的方法 | |
| JP2018537962A5 (enExample) | ||
| JP2021107397A (ja) | 抗ｉｌ２３抗体を使用してクローン病を治療するための方法 | |
| TW201124427A (en) | IL-1 binding proteins | |
| TW201333033A (zh) | 雙可變域免疫球蛋白及其用途 | |
| KR20130080058A (ko) | Ｉｌ-12/ｐ40 결합 단백질 | |
| TW201333039A (zh) | 雙可變域免疫球蛋白及其用途 | |
| CN104159920A (zh) | 针对il-13和/或il-17的双重可变结构域免疫球蛋白 | |
| JP2012516153A (ja) | Ｉｌ−１結合タンパク質 | |
| TW201446800A (zh) | 針對ＴＮＦα之雙特異性結合蛋白 | |
| JP2021509274A (ja) | モノクローナル抗体およびその使用法 | |
| US11932683B2 (en) | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | |
| CN112839952A (zh) | 包含基于pd-1的嵌合蛋白的组合疗法 | |
| JP2018529661A5 (enExample) | ||
| ES2985731T3 (es) | Tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica mediante antagonismo de IL-20R | |
| US11993654B2 (en) | PD-1 binding domains | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| JP2025518805A (ja) | インターフェロン－ガンマ抗体を用いて白斑を処置する方法 | |
| EP4313311A1 (en) | Multispecific binding moieties comprising novel pd-1 binding domains | |
| WO2025247306A1 (zh) | Ox40l结合分子及其用途 | |
| TW202031681A (zh) | 經工程處理之Fc |